Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | OCI/AML-2; OCIAML-2; OCI-AML2; OCI/AML2; OCI AML2; OCIAML2; AML-2 |
| Species | Human |
| Cat.No | ABC-TC480S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Acute Myeloid Leukemia |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
OCI-AML2 is a human acute myeloid leukemia (AML) cell line derived from the peripheral blood of a 65-year-old male diagnosed with FAB M4 subtype in 1986. These cells exhibit typical round to oval morphology and grow in suspension without adherence. OCI-AML2 expresses hepatocyte growth factor (HGF), resulting in autocrine activation of the MET receptor tyrosine kinase, which supports cell survival, proliferation, and disease progression. The cell line is tumorigenic and capable of metastasis, making it highly suitable for studying AML signaling pathways, drug sensitivity, and disease relapse. Cells are pathogen-free (mycoplasma, bacteria, yeast, fungi), non-viral (HPV, HIV-negative), and are cryopreserved for consistent experimental use. It is widely used in both academic and pharmaceutical leukemia research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
OCI-AML2 cell line is broadly applied in leukemia research. It serves as a valuable tool for investigating AML cell biology and treatment response of acute myeloid leukemia (AML) cells. Researchers rely on OCI-AML2 to gain insights into the role of DNMT3A in leukemogenesis and to establish connections between drug response and DNMT3A mutational status across different AML genetic backgrounds. Furthermore, OCI-AML2 is employed in the designing targeted therapies against AML-driving receptors in AML by designing approaches that block compensatory ligand expression.
OCI-AML2 is a human acute myeloid leukemia (AML) cell line used in leukemia research.
The recommended culture medium is alpha-MEM supplemented with 20% fetal bovine serum.
The medium should be changed every 2-3 days to ensure optimal growth conditions.
Approximately 1×10^5 cells/mL.
